![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
NeuroSearch A/S, Ballerup, Denmark
Accumulating preclinical data suggest that compounds that block the excitatory effect of glutamate on the kainate subtype of glutamate receptors may have utility for the treatment of pain, migraine, and epilepsy. In the present study, the in vitro pharmacological properties of the novel glutamate antagonist 5-carboxyl-2,4-di-benzamido-benzoic acid (NS3763) are described. In functional assays in human embryonic kidney (HEK)293 cells expressing homomeric GLUK5 or GLUK6 receptors, NS3763 is shown to display selectivity for inhibition of domoate-induced increase in intracellular calcium mediated through the GLUK5 subtype (IC50 = 1.6 µM) of kainate receptors compared with the GLUK6 subtype (IC50 > 30 µM). NS3763 inhibits the GLUK5-mediated response in a noncompetitive manner and does not inhibit [3H]
-amino-3-hydroxy-5-tertbutylisoxazole-4-propionic acid binding to GLUK5 receptors. Furthermore, NS3763 selectively inhibits L-glutamate- and domoate-evoked currents through GLUK5 receptors in HEK293 cells and does not significantly inhibit
-amino-3-hydroxy-5-methylisoxazole-4-propionic acid- or N-methyl-D-aspartate-induced currents in cultured mouse cortical neurons at 30 µM. This is the first report on a selective and noncompetitive GLUK5 antagonist.
Address correspondence to: Dr. Elsebet Ø. Nielsen, Department of Receptor Biochemistry, NeuroSearch A/S, 93 Pederstrupvej, DK-2750 Ballerup, Denmark. E-mail: eon{at}neurosearch.dk
This article has been cited by other articles:
![]() |
J.-C. Platel, T. Heintz, S. Young, V. Gordon, and A. Bordey Tonic activation of GLUK5 kainate receptors decreases neuroblast migration in whole-mounts of the subventricular zone J. Physiol., August 15, 2008; 586(16): 3783 - 3793. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. Lash, J. M. Sanders, N. Akiyama, M. Shoji, P. Postila, O. T. Pentikainen, M. Sasaki, R. Sakai, and G. T. Swanson Novel Analogs and Stereoisomers of the Marine Toxin Neodysiherbaine with Specificity for Kainate Receptors J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 484 - 496. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Weiss, A. Alt, A. M. Ogden, M. Gates, D. K. Dieckman, A. Clemens-Smith, K. H. Ho, K. Jarvie, G. Rizkalla, R. A. Wright, et al. Pharmacological Characterization of the Competitive GLUK5 Receptor Antagonist Decahydroisoquinoline LY466195 in Vitro and in Vivo J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 772 - 781. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Sanders, O. T. Pentikainen, L. Settimo, U. Pentikainen, M. Shoji, M. Sasaki, R. Sakai, M. S. Johnson, and G. T. Swanson Determination of Binding Site Residues Responsible for the Subunit Selectivity of Novel Marine-Derived Compounds on Kainate Receptors Mol. Pharmacol., June 1, 2006; 69(6): 1849 - 1860. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Sanders, K. Ito, L. Settimo, O. T. Pentikainen, M. Shoji, M. Sasaki, M. S. Johnson, R. Sakai, and G. T. Swanson Divergent Pharmacological Activity of Novel Marine-Derived Excitatory Amino Acids on Glutamate Receptors J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1068 - 1078. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Christensen, A. V. Paternain, S. Selak, P. K. Ahring, and J. Lerma A Mosaic of Functional Kainate Receptors in Hippocampal Interneurons J. Neurosci., October 13, 2004; 24(41): 8986 - 8993. [Abstract] [Full Text] [PDF] |
||||